Vilon (20mg)

Description

Vilon Peptide

Vilon is a dipeptide composed of amino acids lysine and glutamic acid. It also goes by the name ‘Lysylglutamic Acid or Lysylglutamate.’⁽¹⁾ It is the shortest peptide suggested to possess potential action in the immune system, possibly mitigate cancer cell proliferation, and potentially induce anti-aging action within cells, possibly working on tissues within the liver, heart, and kidney. Vilon appears to exert its potential by possible interaction with the chromatin structure.

Vilon peptide research has also led to the postulating of several research hypotheses, including that the peptide may act to unroll chromatin structures, that it may activate ribosomal genes stimulating the synthetic process, that it may release inactive genes, and that it may not decondense the chromatin situated on each side of the centromere of the chromosome. Through its potential action on the chromatin, Vilon may possibly alter DNA structure to reactivate the genes and cells that have gone ‘silent.’

Overview

Considered a bioregulator peptide, researchers speculate that Vilon may potentially support functions within the immune system, including in immunocompromised animal models. Researchers suggest Vilon may activate the interleukin-2 protein in spleen cells, which is considered critical in maintaining immune function.⁽³⁾ It may stimulate the organism to fight against microbial infection and foreign bodies and prevent harmful autoimmune responses. Vilon has been suggested to activate white blood and spleen cells and potentially naturally boost the organism to protect against autoimmune elements.

A study was conducted in 2002 with three bioregulatory peptides to study their potential on interleukin-2 mRNA synthesis in spleen cells. According to this study, “The intensity of interleukin-2 mRNA synthesis in splenocytes depended on the type, concentration, and duration of [exposure] with the peptides. Vilon and Epithalon were most potent, while Cortagen produced a less pronounced effect on interleukin-2 mRNA synthesis.”⁽³⁾

Furthermore, research suggests that Vilon peptides may possibly mitigate autoimmune action by interacting with the thymus gland. The thymus gland is considered responsible for the proliferation of T-helper cells, and with the help of the Vilon peptide, this proliferation may be further enhanced. As per N N Sevostianiva et al., the Vilon peptide is “considered as a bioactive substance possessing immunomodulator and antiallergic activity.” ⁽⁴⁾ The research indicates that there is a potential for Vilon to enhance the expression of the CD5 molecule in embryonic thymic cells. Specifically, the data revealed a tentative increase of 78% in the expression levels of CD5 in rat thymic cells and a 45% increase in embryonic thymic cells compared with the baseline levels in the control group. CD5 is a marker important in the development and maturation of T-cells in the thymus, an organ considered pivotal for the generation of immune cells. The study further hypothesizes that Vilon may influence the maturation process of thymic cells, potentially steering the development of T-cell precursors more toward becoming CD4+ T-helper cells. T-helper cells are deemed critical components of the adaptive immune system, aiding in the activation and direction of other immune cells. You may also be interested in our related research peptides, including Tripeptide, Sermorelin Peptide, Hexarelin, Melanotan 1, Oxytocin Peptide, Snap 8 Peptide, Pinealon, Kisspeptin 10 mg, VIP Peptide, and ARA 290 Peptide.

Chemical Makeup

Molecular formula: C₁₁H₂₁N₃O₅
Molecular weight: 257.30g/mol
Other known titles: Lysylglutamate, normophthal, Lysylglutamic acid

Vilon Research and Clinical Studies

Extended research has produced a wide variety of hypotheses speculating on the action of the Vilon peptide, some detailed below:

Vilon Peptide and Cellular Lifespan

Vilon may potentially extend the average lifespan of certain animal models under laboratory conditions through an extension and mitigation of cell death. As stated above, Vilon has been suggested to exhibit potential in enhancing the immune system, improving physical endurance and energy levels, thereby possibly increasing average lifespan of animal test models.⁽⁵⁾ Vilon is advised to study earlier in the test model lifespan rather than later for clearest possible action. Researchers hypothesize when a bioregulator like Vilon is exposed in vivo in lab models, it may only reverse ‘silent’ cells, exerting no apparent action on cells killed via apoptosis.

In another experiment, researchers explored the potential of Vilon on spleen organotypic tissue cultures derived from murine models of differing ages. The findings from this investigation suggest that Vilon potentially influences the development of the explants.⁽⁶⁾ Further research investigated research models where the peptide was introduced into the cultural medium of tissue explants derived from murine models at varying stages of development: 3 days, 3 weeks, and 2 years old. It was posited that Vilon induces morphological stability in the tissues while potentially activating both regeneration and functional activity of the cells involved. Interestingly, the results suggest that the impact of Vilon appeared to be more pronounced in explants from older murine models. This observation leads to the hypothesis that Vilon may have potential relevance in geriatric research, focusing on the mechanisms of cell aging and regeneration. The possibility that Vilon preferentially supports older tissues might be indicative of its role in modulating age-related cellular mechanisms or promoting stability in more senescent cells.⁽⁷⁾

Another study examined the actions of low amounts of ionizing radiation, which apparently leads to accelerated cell aging of the thymus and spleen in murine models. Vilon was tested for its potential to mitigate this accelerated cellular aging process. The researchers tentatively suggest that Vilon partially inhibited the pro-aging action induced by the radiation. This research posits that Vilon might be of interest in the field of geriatric research, potentially as an agent to manage or reduce the impacts of cell aging in critical immune organs post-radiation exposure. The study highlights Vilon’s potential role in preserving organ function in an irradiated environment, which may be crucial for developing strategies against radiation-induced degeneration in murine models.⁽⁸⁾

Vilon Peptide and Carcinogenic Cells

Several studies suggest that peptide exhibits the potential to prevent some spread of carcinogenic cells by preventing the formation of new tumors, and potentially inhibiting existing tumors’ growth.⁽⁹⁾ Another study examined the potential of Vilon on the development of urinary bladder carcinogenesis in murine models exposed to N-butyl-N-(4-hydroxybutyl)nitrosamine (BBNA).⁽¹⁰⁾ The experiment included a control group and a Vilon-exposed group. Each group began with 50 rats, all of which received BBNA. The primary observation was that the incidence of urinary bladder cancer cells was lower in the Vilon-exposed group compared to the control group. Specifically, cancer cells developed in 56% of the Vilon-exposed murine models versus 75.5% of the controls. This data possibly indicates that Vilon may have a moderating action on cancer cell development when exposed to BBNA. Further, the study noted a reduction in both the prevalence and severity of preneoplastic and early neoplastic changes in the urinary bladder mucosa in the Vilon-exposed murine models. In terms of morphological changes, the study reported fewer hyperplastic changes and lower malignancy rates in the Vilon group. There was a noticeable delay in the malignization of epithelial tissues in the Vilon group, suggesting a potential role of Vilon in modulating the rate or extent of tumor malignancy. Additionally, the average number of tumors per animal was lower in the Vilon group (1.5 tumors per rat) compared to the control group (2.6 tumors per rat), and the tumor cells in the Vilon-exposed rats appeared to manifest with a less aggressive growth pattern. The reduction in tumor aggressiveness and prevalence might indicate that Vilon has the potential to modulate the carcinogenic actions of BBNA. The findings suggest that Vilon, potentially acting as an immunomodulator, might inhibit the early stages of carcinogenesis as well as tumor progression in experimental models.

One study contradicts this potential property of Vilon. According to this study, when used with chemotherapeutic agents derived from platinum ions, this peptide–platinum combination may be more harmful than helpful.⁽¹¹⁾ Unfortunately, since this study only considers one specific type of chemotherapeutic action, the results reported by researchers may be inconclusive.